Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 7681 results

  1. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development [GID-TA11360] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Benralizumab for previously treated severe nasal polyps [ID1659]

    Awaiting development [GID-TA10818] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    Awaiting development [GID-TA11021] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development [GID-TA10748] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    Awaiting development [GID-TA11307] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]

    In development [GID-TA11042] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer ID 6471

    Awaiting development [GID-TA11490] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development [GID-TA10904] Expected publication date: 15 January 2025

    Technology appraisal guidance
    In development

  10. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

    In development [GID-TA10571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  11. Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475

    Awaiting development [GID-TA11586] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Linzagolix for treating symptoms of endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  13. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

    In development [GID-TA11437] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Acne

    Awaiting development [GID-QS10036] Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Primary hyperparathyroidism

    Awaiting development [GID-QS10089] Expected publication date: TBC

    Quality standard
    Awaiting development